Castle Biosciences (CSTL) Net Income towards Common Stockholders (2018 - 2026)

Castle Biosciences has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$14.5 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$14.5 million, up 43.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.8 million (down 153.15% YoY), and the FY2025 annual result was -$24.2 million, down 232.41% from the prior year.
• Net Income towards Common Stockholders came in at -$14.5 million for Q1 2026 at Castle Biosciences, down from -$2.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.6 million in Q4 2024 to a low of -$29.2 million in Q1 2023.
• The 5-year median for Net Income towards Common Stockholders is -$2.6 million (2023), against an average of -$8.5 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 1039.38% in 2023 and soared 471.71% in 2024, its largest moves.
• Castle Biosciences' Net Income towards Common Stockholders stood at -$20.6 million in 2022, then surged by 87.49% to -$2.6 million in 2023, then jumped by 471.71% to $9.6 million in 2024, then sank by 124.32% to -$2.3 million in 2025, then sank by 522.73% to -$14.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$14.5 million (Q1 2026), -$2.3 million (Q4 2025), and -$501000.0 (Q3 2025), per Business Quant data.